$-0.25 EPS Expected for Adaptimmune Therapeutics plc (ADAP)

March 11, 2018 - By Hazel Jackson

 $ 0.25 EPS Expected for Adaptimmune Therapeutics plc (ADAP)

Analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to report $-0.25 EPS on March, 12.They anticipate $0.03 EPS change or 13.64 % from last quarter’s $-0.22 EPS. The stock increased 8.09% or $0.68 during the last trading session, reaching $9.09. About 775,792 shares traded or 77.87% up from the average. Adaptimmune Therapeutics plc (NASDAQ:ADAP) has declined 43.56% since March 11, 2017 and is downtrending. It has underperformed by 60.26% the S&P500.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Ratings Coverage

Among 5 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Adaptimmune Therapeutics PLC had 5 analyst reports since February 25, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Saturday, November 11 by SunTrust. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The company was downgraded on Monday, October 24 by Bank of America. The firm has “Buy” rating given on Tuesday, June 6 by Cowen & Co.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. The company has market cap of $851.61 million. The Company’s platform enables to identify cancer targets; find and genetically engineer T-cell receptors ; and produce TCR therapeutic candidates for administration to patients. It currently has negative earnings. The company's lead program includes NY-ESO-1 and LAGE-1a cancer antigens, which are in Phase I/II clinical trials for patients with solid tumors, as well as hematological cancer types, including synovial sarcoma, multiple myeloma, non-small cell lung cancer (NSCLC), and ovarian cancer; and pilot trial for myxoid round cell liposarcoma.

More news for Adaptimmune Therapeutics plc (NASDAQ:ADAP) were recently published by: Marketwatch.com, which released: “Adaptimmune Therapeutics PLC ADR” on March 04, 2016. Quotes.Wsj.com‘s article titled: “Adaptimmune Therapeutics PLC ADR ADAP (US: Nasdaq)” and published on November 29, 2014 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.